Clinical Trial Update: Phase 3 Efficacy and Safety Study of CD07805/47 Topical Gel in Subjects With Persistent Facial Erythema [Phase 3]

View source ↗

Summary

The document notes that the Phase 3 study of CD07805/47 topical gel for persistent facial erythema has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Erythema

Drugs mentioned

• CD07805/47 Topical Gel (CD07805/47 topical gel)

Snippet

Sponsor: Galderma R&D | Conditions: Erythema | Phase 3 | Status: WITHDRAWN